ROSEN, A LEADING LAW FIRM, Encourages Spero Therapeutics, Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action – SPRO
June 12, 2022 11:00 ET
|
The Rosen Law Firm PA
NEW YORK, June 12, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Spero Therapeutics, Inc. (NASDAQ: SPRO) between October...
DEADLINE ALERT for CDNA, SPRO, and LMPX: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
June 09, 2022 11:45 ET
|
The Law Offices of Frank R. Cruz
LOS ANGELES, June 09, 2022 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following...
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Spero Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – SPRO
June 05, 2022 17:15 ET
|
The Rosen Law Firm PA
NEW YORK, June 05, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Spero...
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 31, 2020 16:45 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., March 31, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Therapeutics Announces Fourth Quarter and Full-Year 2019 Operating Results and Provides Pipeline Update
March 16, 2020 08:45 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., March 16, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Therapeutics Receives FDA Orphan Drug Designation for SPR720 for the Treatment of Nontuberculous Mycobacterial (NTM) Infection
March 11, 2020 08:30 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., March 11, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Therapeutics Announces Closing of Rights Offering
March 05, 2020 16:01 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., March 05, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 28, 2020 17:00 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 28, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Therapeutics to Present at March Investor Conferences
February 26, 2020 16:00 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Therapeutics Announces Commencement of Rights Offering
February 11, 2020 08:00 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 11, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...